•
Jun 30, 2021

Glaukos Q2 2021 Earnings Report

Glaukos's second quarter performance was strong, marked by substantial revenue growth and improved gross margins.

Key Takeaways

Glaukos Corporation reported a significant increase in net sales for Q2 2021, with a 147% increase to $78.1 million compared to $31.6 million in Q2 2020. The company's gross margin also improved to approximately 77%, and non-GAAP gross margin reached approximately 84%.

Net sales increased by 147% to $78.1 million compared to Q2 2020.

Glaucoma net sales reached $62.7 million.

Corneal Health net sales totaled $15.4 million.

Gross margin was approximately 77%, and non-GAAP gross margin was approximately 84%.

Total Revenue
$78.1M
Previous year: $31.6M
+147.5%
EPS
-$0.11
Previous year: -$0.61
-82.0%
Gross margin
77%
Previous year: 31%
+148.4%
Non-GAAP gross margin
84%
Previous year: 78%
+7.7%
SG&A expenses
$45.3M
Previous year: $38.1M
+18.9%
Gross Profit
$60.3M
Previous year: $9.89M
+510.1%
Cash and Equivalents
$118M
Previous year: $267M
-55.7%
Free Cash Flow
-$3.97M
Previous year: -$13.7M
-70.9%
Total Assets
$1.04B
Previous year: $996M
+4.8%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2021 net sales to be in the range of $285 million to $290 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income